Literature DB >> 31313375

Malt1 deficient mice develop osteoporosis independent of osteoclast-intrinsic effects of Malt1 deficiency.

Mahdis Monajemi1, Shera Fisk1, Yvonne C F Pang1, Jessica Leung1, Susan C Menzies1, Rym Ben-Othman2, Bing Cai2, Tobias R Kollmann3, Jacob Rozmus4, Laura M Sly1,3.   

Abstract

This study tested the hypothesis that mucosa associated lymphoid tissue 1 (Malt1) deficiency causes osteoporosis in mice by increasing osteoclastogenesis and osteoclast activity. A patient with combined immunodeficiency (CID) caused by MALT1 deficiency had low bone mineral density resulting in multiple low impact fractures that was corrected by hematopoietic stem cell transplant (HSCT). We have reported that Malt1 deficient Mϕs, another myeloid cell type, are hyper-responsive to inflammatory stimuli. Our objectives were to determine whether Malt1 deficient mice develop an osteoporosis-like phenotype and whether it was caused by Malt1 deficiency in osteoclasts. We found that Malt1 deficient mice had low bone volume by 12 weeks of age, which was primarily associated with reduced trabecular bone. Malt1 protein is expressed and active in osteoclasts and is induced by receptor activator of NF-κB ligand (RANKL) in preosteoclasts. Malt1 deficiency did not impact osteoclast differentiation or activity in vitro. However, Malt1 deficient (Malt1-/- ) mice had more osteoclasts in vivo and had lower levels of serum osteoprotegerin (OPG), an endogenous inhibitor of osteoclastogenesis. Inhibition of Malt1 activity in Mϕs induced MCSF production, required for osteoclastogenesis, and decreased OPG production in response to inflammatory stimuli. In vitro, MCSF increased and OPG inhibited osteoclastogenesis, but effects were not enhanced in Malt1 deficient osteoclasts. These data support the hypothesis that Malt1 deficient mice develop an osteoporotic phenotype with increased osteoclastogenesis in vivo, but suggest that this is caused by inflammation rather than an effect of Malt1 deficiency in osteoclasts. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  Malt1; combined immunodeficiency; macrophage colony-stimulating factor; macrophages; osteoclasts; osteoporosis; osteoprotegerin

Mesh:

Substances:

Year:  2019        PMID: 31313375     DOI: 10.1002/JLB.5VMA0219-054R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  4 in total

1.  MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.

Authors:  Jie Yuan; Lei Xiang; Feng Wang; Lin Zhang; Gaozhan Liu; Xiuli Chang; Anbing Zhang; Ying Tao
Journal:  J Clin Lab Anal       Date:  2022-05-27       Impact factor: 3.124

2.  Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.

Authors:  Zhuang Ye; Lu Chen; Ying Fang; Ling Zhao
Journal:  J Clin Lab Anal       Date:  2021-11-17       Impact factor: 2.352

3.  Dietary resistant starch alleviates Escherichia coli-induced bone loss in meat ducks by promoting short-chain fatty acid production and inhibiting Malt1/NF-κB inflammasome activation.

Authors:  Huaiyong Zhang; Simeng Qin; Xiangli Zhang; Pengfei Du; Yao Zhu; Yanqun Huang; Joris Michiels; Quifeng Zeng; Wen Chen
Journal:  J Anim Sci Biotechnol       Date:  2022-08-05

Review 4.  Osteoporosis pathogenesis and treatment: existing and emerging avenues.

Authors:  Shu Lin; Yan-Chuan Shi; Bo Liang; George Burley
Journal:  Cell Mol Biol Lett       Date:  2022-09-04       Impact factor: 8.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.